1. What Is the Lung Cancer Therapeutics Market?
The Lung Cancer Therapeutics Market covers pharmaceutical treatments for non-small cell lung cancer and small cell lung cancer including targeted therapies, immunotherapy, chemotherapy, and antibody-drug conjugates. Lung cancer therapeutics encompasses EGFR, ALK, ROS1, KRAS, MET, and RET targeted inhibitors, PD-1 and PD-L1 immunotherapy, and bispecific antibody combinations. Market dynamics reflect KRAS G12C inhibitor approval expanding targetable mutations beyond EGFR and ALK, immunotherapy improving long-term survival, and ADC sotorasib combination expanding targeted therapy in molecular subsets.
2. Lung Cancer Therapeutics Market Size & Forecast
3. Emerging Technologies
- Bispecific antibodies targeting PD-1 and TIGIT simultaneously block two complementary immune checkpoint pathways within a single molecular construct, addressing resistance mechanisms in anti-PD-1 monotherapy. Roche's tiragolumab plus atezolizumab SKYSCRAPER-01 Phase 3 data and AstraZeneca's volrustomig programme are defining the clinical validation path for PD-1 and TIGIT bispecific in first-line NSCLC.
- EGFR exon 20 insertion inhibitor amivantamab and mobocertinib addressing a resistance mutation subset are advancing as precision therapy tools. Growing adoption is driven by EGFR exon 20 mutation prevalence in 8 to 10 percent of EGFR-mutant NSCLC.
- CtDNA liquid biopsy minimal residual disease monitoring guiding adjuvant therapy decisions in resected NSCLC are advancing as precision oncology tools. Growing adoption at NSCLC surgery programmes is driven by recurrence risk stratification requirements.
- Antibody-drug conjugate combinations with immunotherapy in NSCLC are advancing as next-line treatment tools. Growing investment is driven by immunotherapy-resistant NSCLC patient treatment requirements.
Similar technologies are also transforming adjacent markets. Learn more in our Oncology Care Model Market.
4. Key Market Opportunity
Demand is strongest in the Lung Cancer Therapeutics Market at the pembrolizumab and immunotherapy combination sub-market, where first-line PD-L1-positive NSCLC generates the largest single oncology indication revenue. KRAS G12C inhibitor combination therapy creates a growing targeted therapy opportunity as sotorasib and adagrasib combination trials expand efficacy. EGFR third-generation osimertinib creates a long-term commercial opportunity as adjuvant and metastatic first-line use maintains market leadership. Asia Pacific lung cancer creates geographic expansion as high smoking prevalence in China, Japan, and Southeast Asia drives the largest patient population globally.
5. Top Companies in the Lung Cancer Therapeutics Market
The following organisations hold leading positions in the Lung Cancer Therapeutics Market. The full report provides revenue share, SWOT analysis, and competitive benchmarking for each player.
- Merck (Pembrolizumab)
- Roche/Genentech (Alectinib, Atezolizumab)
- AstraZeneca (Osimertinib, Durvalumab)
- Amgen (Sotorasib)
- Mirati (Adagrasib)
- Bristol-Myers Squibb (Nivolumab)
- Novartis (Capmatinib)
- Blueprint Medicines (Pralsetinib)
- Eli Lilly (Ramucirumab)
- Daiichi Sankyo (Datopotamab Deruxtecan)
6. Market Segmentation
The Lung Cancer Therapeutics Market is analysed across 4 segmentation dimensions. Revenue data, growth rates, and competitive intensity by sub-segment are available in the full report.
| Segmentation | Sub-Segments |
|---|---|
| By Drug Class | EGFR TKI ALK Inhibitor KRAS G12C PD-1/PD-L1 ADC Chemotherapy |
| By NSCLC Subtype | EGFR-Mutant ALK-Positive KRAS G12C PD-L1 High SCLC |
| By Line | First-Line Second-Line Maintenance |
| By Geography | North America Europe Asia Pacific Latin America Middle East and Africa |
7. Key Market Trends (2026–2034)
Three major forces are shaping the Lung Cancer Therapeutics Market trajectory over the forecast period:
Merck Keytruda Achieves USD 25 Billion Annual Revenue With Lung Cancer as the Largest Oncology Indication.Merck pembrolizumab achieving USD 25 billion annual global revenue in 2024 with 45 percent attributable to NSCLC indications demonstrates lung cancer as the largest single pembrolizumab indication. Keytruda first-line approval in PD-L1-high NSCLC, combination chemo-immuno therapy, and second-line all-comers create broad commercial coverage across NSCLC treatment lines.
Amgen Lumakras KRAS G12C Sotorasib Achieves USD 450 Million Annual Revenue in First KRAS-Targeted Approval.Amgen sotorasib achieving USD 450 million and Mirati adagrasib reaching USD 300 million combined KRAS G12C inhibitor revenue in 2024 demonstrate the new targetable mutation class generating commercial revenue. KRAS G12C mutation prevalence in 13 percent of NSCLC creates a defined commercial segment for the first-ever KRAS-targeted lung cancer therapy.
Roche Alecensa Achieves 5-Year PFS in ALK-Positive NSCLC Demonstrating Long-Term Targeted Therapy Benefit.Roche alectinib 5-year progression-free survival of 62 percent in ALK-positive NSCLC from ALEX trial long-term follow-up in 2024 demonstrates sustained targeted therapy benefit beyond prior ALK inhibitor generations. ALK-positive NSCLC representing 5 percent of NSCLC with long-term targeted therapy survival creates a defined high-value commercial patient segment.
For related market intelligence, see the Cancer Registry Market.
8. Segmental Analysis
By drug class, the PD-1/PD-L1 Immunotherapy segment dominated the Lung Cancer Therapeutics Market in 2025. Representing the largest revenue category as pembrolizumab, nivolumab, and atezolizumab generate the majority of NSCLC pharmaceutical revenue. The KRAS G12C Inhibitor segment is the fastest-growing category, advancing as sotorasib and adagrasib combination trials expand clinical utility.
By subtype, EGFR-mutant NSCLC dominated in 2025 by patient volume, while KRAS G12C is registering the highest revenue growth rate.
By NSCLC subtype, the EGFR-Mutant segment dominated the Lung Cancer Therapeutics Market in 2025, as the largest molecularly targeted NSCLC population generates the highest targeted therapy revenue across first, second, and third-generation EGFR inhibitor prescribing. KRAS G12C is the fastest-growing subtype category, driven by sotorasib and adagrasib approval creating the first druggable KRAS treatment for a previously undruggable mutation.
By treatment line, the First-Line segment dominated the Lung Cancer Therapeutics Market in 2025, as biomarker-selected first-line targeted therapy and immunotherapy combinations generate the largest prescribing volume and revenue across all NSCLC therapeutic categories. Maintenance therapy is the fastest-growing line category, driven by expanding evidence for immune checkpoint inhibitor continuation and targeted therapy maintenance improving progression-free survival.
9. Regional Analysis
Regional demand patterns across the Lung Cancer Therapeutics Market reflect differences in regulation, technological maturity, and capital investment.
Largest Market Share
North America accounted for the largest share of the Lung Cancer Therapeutics Market in 2025, holding 46.8% of the global market. Oncology centres, thoracic surgery programmes, and pharmaceutical companies are conducting the world's largest volume of lung cancer clinical research, immunotherapy combination studies, and targeted therapy clinical trials. FDA approval of multiple first-line and subsequent-line lung cancer therapies and growing pharmaceutical investment in bispecific antibody and antibody-drug conjugate development for NSCLC are encouraging treatment innovation. High lung cancer incidence, large clinical trial patient populations, and strong pharmaceutical and academic oncology research investment are generating dominant regional therapeutic development.
Highest CAGR Region
Asia Pacific is expected to register the highest CAGR of 15.18% during the forecast period. The high incidence of lung cancer across China, Japan, South Korea, and India, driven by smoking prevalence and air quality factors, is creating large clinical demand for improved lung cancer therapeutic approaches. Growing pharmaceutical investment in EGFR-mutant and ALK-positive lung cancer targeted therapies with regional biomarker prevalence advantages is generating targeted treatment development. Increasing oncology treatment infrastructure investment and expanding access to precision oncology biomarker testing across the region are generating demand for lung cancer therapeutics.
10. Full Report with Exclusive Insights
The complete published market report includes an in-depth analysis of market dynamics, industry trends, competitive landscape, regional outlook, and future growth opportunities. The study provides detailed market sizing and forecasts across key segments and geographies, along with comprehensive insights into drivers, restraints, opportunities, challenges, technological advancements, regulatory landscape, and evolving consumer and industry trends. The report also features company profiles, strategic developments, market share analysis, and actionable recommendations to support informed business decision-making. Additionally, the syndicated report package typically includes forecast datasets, charts and figures, research methodology, and analyst support for strategic interpretation and planning.
Advanced Strategic & Custom Intelligence
In addition to the standard syndicated report package, TrendX Insights can provide the following advanced strategic analyses and customized intelligence solutions for any market:
Standard Report Coverage
- • Competitor Analysis
- • Country Trade Analysis
- • Import & Export Analysis
- • Porter’s Five Forces Analysis
- • SWOT Analysis by Companies
- • TrendX Insights Quadrant Positioning
- • Pricing Analysis
- • Detailed Macro-Economic Indicators Assessment
- • List of Raw Material Suppliers
- • Regulatory Framework Assessment
- • Supply Chain Resilience Mapping
- • Value Chain Analysis
- • Technology Adoption Trends and Innovation Tracking
- • Custom Company Profiling and Benchmarking
Exclusive Sections With Additional Cost
- • Agentic AI Readiness Score
- • TAM, SAM, and SOM Analysis
- • AI Act & Privacy Compliance Audit
- • Channel Partner Ecosystem Mapping
- • China + 1 Strategy Analysis
- • Circular Economy Opportunities Assessment
- • Competitor Benchmarking KPI Analysis
- • Country-Level Opportunity Mapping
- • Digital Maturity Matrix
- • Ecosystem Interdependency Mapping
- • ESG & Decarbonization Roadmap
- • Geopolitical Friction Scorecard
- • Geopolitical Risk Assessment
- • Humanoid Workforce Impact Analysis
- • Investment Heatmap
- • List of Distributors and Channel Partners
- • Market Entry Strategy Assessment
- • Mergers & Acquisitions (M&A) Analysis
- • Patent & Intellectual Property (IP) Analysis
- • Pilot Project Analysis
- • Potential High-Growth Region/Country Investment Assessment
- • Product Comparison Analysis
- • Product Revenue Analysis
- • R&D Investment Analysis in Emerging Technologies
- • Raw Material Scarcity Forecast
Note: For highly customized requirements, deeper strategic assessments, company-specific intelligence, or tailored consulting support, please contact TrendX Insights.
Full Report with Exclusive Insights
Available to clients on request
Explore Our Published Reports Library
This page covers market-level data estimates. For comprehensive published research reports including full methodology, primary data, and detailed company profiles, browse the TrendX Insights Published Reports Library.
Visit Published Reports Library ›11. Related Market Reports
Frequently Asked Questions
The Lung Cancer Therapeutics Market was valued at USD 38.60 Bn in 2025 and is projected to reach USD 101.17 Bn by 2034, growing at a CAGR of 11.3% over the 2026–2034 forecast period.
The Lung Cancer Therapeutics Market is projected to grow at a CAGR of 11.3% from 2026 to 2034.
North America accounted for the largest share of the Lung Cancer Therapeutics Market in 2025, holding 46.8% of the global market.
The leading companies in the Lung Cancer Therapeutics Market include Merck (Pembrolizumab), Roche/Genentech (Alectinib, Atezolizumab), AstraZeneca (Osimertinib, Durvalumab), Amgen (Sotorasib), Mirati (Adagrasib), Bristol-Myers Squibb (Nivolumab), Novartis (Capmatinib), Blueprint Medicines (Pralsetinib), Eli Lilly (Ramucirumab), Daiichi Sankyo (Datopotamab Deruxtecan).
Merck keytruda achieves usd 25 billion annual revenue with lung cancer as the largest oncology indication.
By drug class, the PD-1/PD-L1 Immunotherapy segment dominated the Lung Cancer Therapeutics Market in 2025.
How to Order
Purchasing a TrendX Insights report is straightforward. Our process is designed to be transparent and risk-free for buyers, with a 20% upfront model and full delivery before the balance payment.
This is the price of the syndicated report. Any custom inclusions beyond the Table of Contents will be scoped and priced separately. For the full list of what is covered in the syndicated report, refer to the Table of Contents tab.
A curated, condensed version of this report for students, researchers, and academic institutions. Ideal for thesis work, dissertations, and academic projects. Delivered as PDF to your institutional email.
Valid student ID or institutional email required. For educational and non-commercial use only.